The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy

(1) Background: A cannabigerol aminoquinone derivative, so-called VCE-003.2, has been found to behave as a neuroprotective agent (administered both i.p. and orally) in different experimental models of Parkinson’s disease (PD) in mice. These effects were exerted through mechanisms that involved the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Carreiro, Santiago, Navarro, Elisa, Muñoz, Eduardo, Fernández-Ruiz, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527302/
https://www.ncbi.nlm.nih.gov/pubmed/37759872
http://dx.doi.org/10.3390/brainsci13091272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527302/
https://www.ncbi.nlm.nih.gov/pubmed/37759872
http://dx.doi.org/10.3390/brainsci13091272

Ejemplares similares